773 A phase I/II study to evaluate the safety, tolerability and preliminary efficacy of GLS-012 monotherapy and in combination with zimberelimab in patients with advanced melanoma (Triumph-01)

• Jun Guo,
• Lu Si,
• Jiman Zhu

Affiliations

Jun Guo

1Peking University Cancer Hospital and Institute, Beijing, China

Lu Si

1Peking University Cancer Hospital and Institute, Beijing, China

Jiman Zhu

2Guangzhou Gloria Biosciences Co., Ltd., Beijing, China